The Union Health Ministry has recommended the use of anti-malarial drug hydroxychloroquine in combination with azithromycin on those severely suffering from Covid-19 who require intensive care unit management. In its revised guidelines on the ‘Clinical Management of Covid-19’ issued on Tuesday, the ministry said the drug is presently not recommended for children aged less than 12 and pregnant and lactating Women.
“No specific antivirals have been proven to be effective as per currently available data. However, based on the available information (uncontrolled clinical trials), the following drugs may be considered as an off label indication in patients with severe disease and requiring ICU management,” the ministry said while recommending the drug combination.
The ministry has removed its earlier recommendation of the use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient suffering from coronavirus infection.
“As per latest clinical data available from across the work, Lopinavir and Ritonavir drug combination was not found to have significant benefit for patients of Covid-19 so it has been discontinued,” a health ministry official said.
This document is intended for clinicians taking care of hospitalised adult and paediatric patients of Covid-19, the guidelines stated. N.Y. Will Start Using Trial Drugs on Tuesday to Treat Patients Best practices for Covid-19 including Infection Prevention and Control and optimized supportive care for severely ill patients are considered essential, it said, adding that the document aim